Zai Lab (ZLAB) received the US Food and Drug Administration's fast track designation for zocilurtatug pelitecan, or zoci, for the treatment of extrapulmonary neuroendocrine carcinomas, the company said Monday.
The designation is intended to expedite the review and development of new drugs targeting an unmet medical need or serious or life-threatening diseases, Zai Lab said.
Zoci was also granted fast track designation for for the treatment of extensive-stage small cell lung cancer in May 2025, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments